CA2979527A1 - Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease - Google Patents

Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease

Info

Publication number
CA2979527A1
CA2979527A1 CA2979527A CA2979527A CA2979527A1 CA 2979527 A1 CA2979527 A1 CA 2979527A1 CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A1 CA2979527 A1 CA 2979527A1
Authority
CA
Canada
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2979527A
Other languages
English (en)
French (fr)
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Longwu Qi
Yingcai Wang
Kevin Yu Wang
Ning Zou
Albert E. FELTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CA2979527A1 publication Critical patent/CA2979527A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2979527A 2015-03-13 2015-03-13 Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease Pending CA2979527A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/020397 WO2016148674A1 (en) 2015-03-13 2015-03-13 Conjugates for treating diseases

Publications (1)

Publication Number Publication Date
CA2979527A1 true CA2979527A1 (en) 2016-09-22

Family

ID=56920017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979527A Pending CA2979527A1 (en) 2015-03-13 2015-03-13 Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease

Country Status (6)

Country Link
US (2) US10624972B2 (enExample)
EP (1) EP3268046A4 (enExample)
JP (1) JP6676650B2 (enExample)
CN (1) CN107847609A (enExample)
CA (1) CA2979527A1 (enExample)
WO (1) WO2016148674A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266303A1 (en) * 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
US20200323991A1 (en) * 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases
CN109475558A (zh) * 2016-05-25 2019-03-15 普渡研究基金会 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP4086268A4 (en) 2019-12-31 2024-08-21 LegoChem Biosciences, Inc. PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
JPH03206886A (ja) 1989-11-13 1991-09-10 Green Cross Corp:The ヒト腫瘍細胞抗原に対し特異性を持つマウス―ヒトキメラａ１０抗体
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH06502301A (ja) 1990-08-29 1994-03-17 サントル　オスピタリエ　レジオナル　デ　ナント 安定タンパク質コアに結合されたタンパク質ポリリガンド
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
WO2001010468A2 (en) * 1999-08-09 2001-02-15 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
JP5576007B2 (ja) 2003-01-27 2014-08-20 エンドサイト・インコーポレイテッド ビタミン受容体結合性薬剤送達結合体
EP2374480A3 (en) * 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
EP2125870A4 (en) 2007-02-16 2011-04-06 Boehringer Ingelheim Int INHIBITORS OF HEPATITIS C NS3 PROTEASE
CN104383553A (zh) * 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
US8546425B2 (en) 2008-09-17 2013-10-01 Purdue Research Foundation Folate receptor binding conjugates of antifolates
WO2011130598A1 (en) * 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
CA2799391A1 (en) 2010-05-19 2011-12-04 Endocyte, Inc. Improved process for a folate-targeted agent
KR20140010076A (ko) * 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
US20130267522A1 (en) * 2012-03-01 2013-10-10 Endocyte, Inc. Methods for treating cancer
JP2015536323A (ja) * 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
AU2013344778C1 (en) * 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
AU2012395148B2 (en) * 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
HK1216176A1 (zh) 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
MY186334A (en) 2014-09-12 2021-07-12 Genentech Inc Anti-her2 antibodies and immunoconjugates
US20170266303A1 (en) 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
US20200323991A1 (en) 2016-03-29 2020-10-15 Endocyte, Inc. Pbd conjugates for treating diseases

Also Published As

Publication number Publication date
EP3268046A1 (en) 2018-01-17
US20180228914A1 (en) 2018-08-16
US10624972B2 (en) 2020-04-21
EP3268046A4 (en) 2018-11-21
JP2018509424A (ja) 2018-04-05
US20200289659A1 (en) 2020-09-17
WO2016148674A1 (en) 2016-09-22
JP6676650B2 (ja) 2020-04-08
CN107847609A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
TWI440641B (zh) 蛋白酶體抑制劑
AU2023203341A1 (en) Silicon based drug conjugates and methods of using same
AU2017277949B2 (en) Silanol based therapeutic payloads
US20200289659A1 (en) Conjugates for treating diseases
US11484600B2 (en) Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof
CZ20023330A3 (cs) Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy
WO2010045598A2 (en) Psma binding ligand-linker conjugates and methods for using
US20200323991A1 (en) Pbd conjugates for treating diseases
WO2016168471A1 (en) Dual disulfide drug conjugates
US10500286B2 (en) CCK2R-drug conjugates
WO2016089879A1 (en) Conjugates of garftase inhibitors
WO2021051720A1 (zh) 一类抗人egfr抗体药物偶联物及其制备方法与应用
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
US20160303251A1 (en) Conjugates of garftase inhibitors
CN115974849B (zh) 一种吲哚氧乙酰胺类衍生物、包含其的药物组合物及其应用
US20180125992A1 (en) Drug delivery conjugates of tertiary amine containing drugs
JP2014509613A (ja) Ｄ−イソグルタミル−［ｄ／ｌ］−トリプトファンのプロドラッグ
JP2020117509A (ja) 疾患を処置するためのコンジュゲート
WO2015069766A1 (en) Dupa-indenoisoquinoline conjugates
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
TW202325273A (zh) 靶向fap之中子捕獲劑及與其相關之用途及調配物
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN121969396A (zh) 胜肽药物复合体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200311

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20240913

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250915

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105